Well now I’m a little confused. From the press release today, and from prior news, I thought PSTI was already cleared for compassionate use in the US. However, from the FDA website, it seems FDA equates Expanded Access Program to Compassionate Use. So perhaps the EAP is not really an expansion of what has already been happening? Or maybe the expansion relates to the number of people that can be treated? :|
Market Data 
Markets 
AI
